AR063697A1 - DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA - Google Patents

DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA

Info

Publication number
AR063697A1
AR063697A1 ARP070103808A AR063697A1 AR 063697 A1 AR063697 A1 AR 063697A1 AR P070103808 A ARP070103808 A AR P070103808A AR 063697 A1 AR063697 A1 AR 063697A1
Authority
AR
Argentina
Prior art keywords
bifeprunox
schizophrenia
patient
compound
treatment
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Antje A Winsemius
Nathan A Shapira
Rosaline Pardue
Vries Michiel H De
Marc Debelle
Jane Heisterberg
Mette Krog Josiassen
Jette Buch Ostergard
Dorte Mailling
Ellen B Christensen
Paul P Yeung
Sangesta Raje
Wurth S A Paul
Saeed Ahmed
Michel Bourin
Daniel E Cassey
Steven G Potkin
Mark Rapaport
John Newcomer
Luigi M Barbato
Original Assignee
Solvay Pharm Bv
Wyeth Corp
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Wyeth Corp, Lundbeck & Co As H filed Critical Solvay Pharm Bv
Publication of AR063697A1 publication Critical patent/AR063697A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una dosis diaria de bifeprunox para el tratamiento de un paciente con esquizofrenia. Tal dosis es efectivamente utilizada en métodos para tratar esquizofrenia que comprenden administrar a un paciente una composición farmacéutica que comprende una cantidad efectiva de al menos un compuesto de bifeprunox, entre otros efectos, dando por resultado una reducción de los efectos secundarios asociados con el tratamiento de la esquizofrenia, tales como: no aumento de peso, mejoría en los niveles de triglicéridos no en ayunas y/o en los niveles de colesterol total. Los efectos del tratamiento son por ej., una reducción en el puntaje total de la PANSS en un paciente y un incremento del tiempo de deterioro de la esquizofrenia y mejoría en los síntomas psicóticos. Reivindicación 28: Bifeprunox para el uso de una cualquiera de las reivindicaciones 19-27, en donde al menos un compuesto de bifeprunox es administrado en combinación con la droga estabilizante del humor litio. Reivindicación 30: Bifeprunox para uso de una cualquiera de las reivindicaciones 19-27, en donde al menos un compuesto de bifeprunox es administrado en combinación con un antidepresivo.A daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such a dose is effectively used in methods to treat schizophrenia which comprise administering to a patient a pharmaceutical composition comprising an effective amount of at least one compound of bifeprunox, among other effects, resulting in a reduction of the side effects associated with the treatment of schizophrenia, such as: no weight gain, improvement in non-fasting triglyceride levels and / or total cholesterol levels. The effects of the treatment are, for example, a reduction in the total PANSS score in a patient and an increase in the time of deterioration of schizophrenia and improvement in psychotic symptoms. Claim 28: Bifeprunox for the use of any one of claims 19-27, wherein at least one compound of bifeprunox is administered in combination with the lithium mood stabilizing drug. Claim 30: Bifeprunox for use of any one of claims 19-27, wherein at least one compound of bifeprunox is administered in combination with an antidepressant.

ARP070103808 2006-08-31 2007-08-28 DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA AR063697A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119936 2006-08-31
EP06120016 2006-09-01

Publications (1)

Publication Number Publication Date
AR063697A1 true AR063697A1 (en) 2009-02-11

Family

ID=40085736

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070103807 AR062561A1 (en) 2006-08-31 2007-08-28 COMPOSITIONS KITS AND METHODS OF A TITULATION PROGRAM FOR BIFEPRUNOX COMPOUNDS
ARP070103808 AR063697A1 (en) 2006-08-31 2007-08-28 DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070103807 AR062561A1 (en) 2006-08-31 2007-08-28 COMPOSITIONS KITS AND METHODS OF A TITULATION PROGRAM FOR BIFEPRUNOX COMPOUNDS

Country Status (4)

Country Link
CN (1) CN101686978A (en)
AR (2) AR062561A1 (en)
MX (2) MX2009002253A (en)
TW (2) TW200829576A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115569123B (en) * 2022-12-08 2023-03-14 则正(济南)生物科技有限公司 Vorinosane fumarate tablet and preparation method thereof

Also Published As

Publication number Publication date
MX2009002254A (en) 2009-07-24
CN101686978A (en) 2010-03-31
TW200817390A (en) 2008-04-16
MX2009002253A (en) 2009-06-04
TW200829576A (en) 2008-07-16
AR062561A1 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
BRPI0507609A (en) therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
AR054064A1 (en) COMPOSITION WITH ACTIVE PHARMACEUTICAL INGREDIENT BASED ON CANABINOID FOR IMPROVED DOSE FORMS
BR112015029491A2 (en) imidazopyrrolidinone derivatives and their use in the treatment of disease
CO6311007A2 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING AN AGENT THAT ACTIVATES REGULATORY T-CELLS CD4 + CD25 +, EFFECTIVE AT LOW DOSE
AR054347A1 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
EA201490279A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
CO6311006A2 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN AGENT THAT ACTIVATES THE REGULATORY T-CELLS CD4 + CD25 + HIGH-DOSE EFFECTIVE
AR070026A1 (en) SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS
PE20170302A1 (en) USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE
AR054234A1 (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
AR082803A1 (en) METHODS AND FORMULATIONS FOR THE TREATMENT OF THROMBOSIS WITH BETRIXABAN AND A GLICOPROTEIN P INHIBITOR
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
PE20061245A1 (en) COMPOSITIONS FOR ORAL TRANSMUCOUS TRANSMISSION OF METFORMIN
ES2656913T3 (en) Endrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors
CO6220945A2 (en) USE OF A COMPOSITION THAT INCLUDES FORMOTEROL AND DIPROPIANATE OF BECLOMETASONE FOR THE PREVENTION AND / OR TREATMENT OF AN EXAMERATION OF ASTHMA
CL2021002107A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
UY30847A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
AR048370A1 (en) COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY
AR045263A1 (en) METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS
PE20090524A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE INHIBITOR AGENT OF SEROTONIN RECAPTURE
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION
AR063697A1 (en) DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal